Jazz Pharmaceuticals acquires Redx’s KRAS inhibitor program February 7, 2024 Alderley Park, UK: Jazz Pharmaceuticals plc and Redx Pharma plc have signed a definitive agreement under which Jazz will acquire Redx’s KRAS (Kirsten rat sarcoma...